Nammi Therapeutics Initiates First Patient Dosing in Phase 1 Study
Nammi Therapeutics, Inc. (Nammi), an innovative clinical-stage immuno-oncology firm, has embarked on an exciting journey with the dosing of the initial patient in a pivotal Phase 1 trial. This study is designed to evaluate QXL138AM in patients with advanced cancer types characterized by CD138 expression. The company's unique platforms, including the Masked-Immunocytokine (MIC) and Nammisome technologies, form the backbone of this groundbreaking research.
Structural Overview of the Phase 1 Study
The Phase 1 clinical trial is structured into two parts: an initial assessment of safety and tolerability, followed by a dose expansion phase. The study aims to enroll approximately 100 participants suffering from advanced cancers that express CD138. Initial stages will monitor escalating doses of QXL138AM, with secondary goals focusing on evaluating pharmacokinetics and immunogenicity to better understand the drug's behavior in the body.
Safety and Tolerability Assessment
Part A of the study specifically targets the safety profile of escalating doses of QXL138AM. It aims to secure vital data on how patients respond to this advanced therapy. The information gathered will be critical for determining the viability of progressing into Part B, which emphasizes dose expansion within selected cohorts.
Dose Expansion and Focused Indications
Part B will direct its efforts toward expanding the dosing regimen across three groups: two solid tumor indications exhibiting high CD138 expression and multiple myeloma. Central to the study are primary endpoints centered on safety and tolerability, while secondary endpoints are dedicated to assessing the anti-tumor efficacy of the treatment.
Insights into QXL138AM's Mechanism
QXL138AM is engineered to enhance the therapeutic window of interferon alpha 2, a potent anti-cancer agent whose clinical utility has been limited by adverse effects during systemic administration. By utilizing Nammi's masked immunocytokine technology, this novel approach seeks to address such limitations. The innovative mechanism involves conjugating interferon alpha 2 with a tumor-targeting antibody that attaches to cancer cells. Once bound, tumor-specific proteases can activate the interferon by removing its protective mask, thereby unleashing its anti-tumor capabilities directly at the site of action.
Perspectives from Leading Researchers
Dr. Dennis Kim, M.D., the chief medical officer for the study, expressed enthusiasm about the advancements, stating, "Interferon alpha 2 has significant anti-cancer potential, but we believe our method of administering it can vastly improve outcomes for patients. By targeting the delivery, we can mitigate harmful side effects and maximize therapeutic effects."
Additionally, Dr. Drew W. Rasco, Associate Director at The START Center for Cancer Research, shared his excitement for the trial’s launch, acknowledging the considerable promise Nammi’s immunocytokine technology brings to various cancer treatments. Both researchers are dedicated to collaborating closely with Nammi, emphasizing the importance of developing and refining these therapies over time.
About Nammi Therapeutics, Inc.
Nammi Therapeutics is on the forefront of fighting cancer through its pioneering immuno-oncology technologies. Based in Los Angeles, the company is focused on creating therapies that selectively modulate the immune response to target tumors while averting systemic activation of the immune system. Nammi aims to enhance patient safety and therapeutic options by adopting a multi-faceted approach utilizing their MIC platform and innovative nanoparticle technology from the Nammisome platform. Numerous candidates from the Nammisome portfolio are currently in the development pipeline, showcasing Nammi's commitment to advancing cancer treatment.
Frequently Asked Questions
What is the goal of Nammi's Phase 1 trial?
The trial aims to assess the safety, tolerability, and anti-tumor activity of QXL138AM in patients with advanced CD138-expressing cancers.
How does QXL138AM work?
QXL138AM leverages a unique mechanism that masks interferon alpha 2, allowing for targeted activation only on tumor cells, thus reducing systemic side effects.
Who is involved in the Phase 1 study?
The study involves several researchers and institutions, with key figures like Dr. Dennis Kim and Dr. Drew W. Rasco contributing their expertise.
What types of cancers are being targeted?
The trial focuses on advanced solid tumors and multiple myeloma, which show expression of the CD138 marker.
What platforms are utilized by Nammi Therapeutics?
Nammi uses the Masked-Immunocytokine (MIC) and Nammisome platforms to develop its innovative cancer treatment technologies.
